Michael Shapiro to Antibodies, Monoclonal
This is a "connection" page, showing publications Michael Shapiro has written about Antibodies, Monoclonal.
Connection Strength
2.359
-
Shapiro MD, Miles J, Tavori H, Fazio S. Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor. Ann Intern Med. 2018 03 06; 168(5):376-379.
Score: 0.519
-
Kaufman TM, Duell PB, Purnell JQ, Wójcik C, Fazio S, Shapiro MD. Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities. Circ Res. 2017 08 18; 121(5):499-501.
Score: 0.509
-
Edmiston JB, Brooks N, Tavori H, Minnier J, Duell B, Purnell JQ, Kaufman T, Wojcik C, Voros S, Fazio S, Shapiro MD. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9. J Clin Lipidol. 2017 May - Jun; 11(3):667-673.
Score: 0.494
-
Shapiro MD, Fazio S, Tavori H. Targeting PCSK9 for therapeutic gains. Curr Atheroscler Rep. 2015 Apr; 17(4):499.
Score: 0.432
-
Mahmood T, Shapiro MD. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology. Curr Opin Cardiol. 2019 09; 34(5):519-525.
Score: 0.147
-
Shapiro MD, Tavori H, Fazio S. PCSK9: From Basic Science Discoveries to Clinical Trials. Circ Res. 2018 05 11; 122(10):1420-1438.
Score: 0.134
-
Shapiro MD, Fazio S. Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL lowering. Nat Rev Cardiol. 2017 06; 14(6):319-320.
Score: 0.125